Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

METAP2 (methionyl aminopeptidase 2)

Written2009-07Ponniah Selvakumar, Rajendra K Sharma
Department of Pathology, Laboratory Medicine, College of Medicine, University of Saskatchewan, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, SK, S7N 4H4, Canada

(Note : for Links provided by Atlas : click)

Identity

Alias_symbol (synonym)MNPEP
p67
MAP2
Other aliasP67EIF2
p67eIF2
HGNC (Hugo) METAP2
LocusID (NCBI) 10988
Atlas_Id 46053
Location 12q22  [Link to chromosome band 12q22]
Location_base_pair Starts at 95867822 and ends at 95909613 bp from pter ( according to hg19-Feb_2009)  [Mapping METAP2.png]
Fusion genes
(updated 2016)
CECR2 (22q11.1) / METAP2 (12q22)ERCC6 (10q11.23) / METAP2 (12q22)GNB3 (12p13.31) / METAP2 (12q22)
METAP2 (12q22) / WDR61 (15q25.1)

DNA/RNA

Description The gene spans 41237 bp on strand plus; 11 exons; coding sequence: 1437 nucleotides.
Pseudogene No known pseudogenes.

Protein

Description Methionine Aminopeptidase 2. E.C. 3.4.11.18. Also known as methionyl aminopeptidase and peptidase M. Catalyzes release of N-terminal amino acids, preferentially methionine, from peptides and arylamides. Methionine aminopeptidases (MetAPs) are the enzymes responsible for the removal of methionine from the amino-terminus of newly synthesized proteins (Jackson and Hunter, 1970; Solbiati et al., 1999). The removal of methionine is essential for further amino terminal modifications (e.g., acetylation by N-alpha-acetyltransferase and myristoylation of glycine by N-myristoyltransferase, NMT) and for protein stability (Selvakumar et al., 2006; Selvakumar et al., 2007; Lowther et al., 2000; Bradshaw et al., 1998).
Expression Ubiquitous expression. MetAP2 protein is highly expressed in all tissues.
Localisation Cytoplasm.
Function This protein function both by protecting the alpha subunit of eukaryotic initiation factor 2 from inhibitory phosphorylation and by removing the amino-terminal methionine residue from nascent protein (Jackson and Hunter, 1970; Solbiati et al., 1999). Increased expression of this gene is associated with various forms of cancer and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site (Selvakumar et al., 2006). This gene is a member of the methionyl aminopeptidase family and encodes a protein that binds to cobalt or manganese ions.
Homology The human MetAP2 has DNA homology with Pan troglodytes (99.7%), Canis lupus familiaris (95%), Bos taurus (95.3%), Mus musculus (89.2%), Rattus norvegicus (89.2%), Gallus gallus (80.8%), Danio rerio (73.5%) and Arabidopsis thaliana (63.8%).
The human MetAP2 has protein homology with Pan troglodytes (100%), Canis lupus familiaris (98.1%), Bos taurus (96.6%), Mus musculus (95%), Rattus norvegicus (94.1%), Gallus gallus (87.6%), Danio rerio (82.9%), and Arabidopsis thaliana (66.2%).

Mutations

Note No mutations have been reported for MetAP2 that cause congenital anomalies.

Implicated in

Note
  
Entity Mesothelioma
Disease Various reports suggested that MetAP2 plays an important role in the growth of different types of tumors. Malignant mesothelioma cells expressed higher MetAP2 mRNA levels compared to normal mesothelioma cells (Catalano et al., 2001). Transfection of mesothelioma cells with a MetAP2 anti-sense oligonucleotide revealed a time-dependent inhibition of cell survival and induced nucleosome formation. MetAP2 is a main regulator of the proliferative and apoptotic pathways in mesothelioma cells and MetAP2 inhibition may represent a potential target for therapeutic intervention in human mesothelioma (Catalano et al., 2001).
  
  
Entity Lymphomas
Disease A high level of MetAP2 was reported in malignant lymphomas exclusively in B-cell lymphoma subtypes (Kanno et al., 2002).
  
  
Entity Colorectal adenocarcinoma
Disease It has been reported that a high expression of MetAP2 in colorectal adenocarcinoma patients (Selvakumar et al., 2004a). Since myristoylation reaction is catalyzed by NMT, we reported that a cross-talk among the MetAP2, and NMT in HT29 cells (Selvakumar et al., 2004b). The expression of pp60c-src, MetAP2, and NMT was dependent on the cell density (Selvakumar et al., 2004b).
  
  
Entity Esophageal squamous carcinoma
Disease Microarray gene expression analysis of human esophageal squamous cell carcinomas revealed that MetAP2 was down-regulated when irradiated (Bo et al., 2004).
  
  
Entity Hepatoma
Disease Anti-sense of MetAP2 also induces apoptosis in rat hepatoma cells (Datta and Datta, 1999). A recent study suggested that fumagillin effectively inhibits both liver tumor growth and metastasis in rats in vivo (Sheen et al., 2005).
  
  
Entity Neuroblastoma
Note The angiogenesis inhibitor TNP470, O-(chloro-acetyl-carbamoyl) fumagillol, a synthetic analogue of fumagillin, suppressed the expression of MetAP2 in human neuroblastoma and thus, MetAP2 may be an important molecular target for human neuroblastomas (Morowitz et al., 2005). The intracellular enzyme MetAP2 became such a candidate target enzyme due to its inactivation by the widely investigated anticancer agent TNP470 (Abe et al., 1994; Adams et al., 2004; Griffith et al., 1997; Hu et et al., 2006; Hu et al., 2007; Sin et al., 1997). Previously, inhibition of MetAP2 by TNP470 has been shown to activate p53 for cell-cycle arrest. In fact, the primary mouse embryonic fibroblasts were demonstrated to be sensitive to TNP470 and other MetAP2-specific inhibitors in a p53-dependent fashion. Several MetAP2 inhibitors were studied based on the inhibition of MetAP activity (Griffith et al., 1998; Antoine et al., 1994; Kusaka et al., 1994; Wang et al., 2000; Wang et al., 2003; Yeh et al., 2000; Zhang et al., 2000; Kim et al., 2004; Towbin et al., 2003).
  
  
Entity Various cancer
Note MetAP2 inhibitors
It has been reported that MetAP2 could function as an oncogene (Tucker et al., 2008). Furthermore, various Src family tyrosine kinases, ADP ribosylation factors and eukaryotic transcription elongation factor-2 were substrates of MetAP2 which plays a significant role in the progression of metastasis (Tucker et al., 2008). A derivative of the natural product fumagillin, TNP470 has been shown to be safe and effective in the treatment of solid tumors in several animal studies and preclinical trials. TNP470 entered human clinical trials for the treatment of AIDS-related Kaposi's sarcoma, metastatic breast cancer, androgen-independent prostate cancer, pediatric solid tumors, lymphomas, acute leukemia, advanced squamous cell cancer of the cervix, and metastatic renal carcinoma (Dezube et al., 1998; Kruger and Figg, 2000; Kudelka et al., 1997). Several MetAP2 inhibitors were studied based on the inhibition of MetAP activity (Griffith et al., 1998; Antoine et al., 1994; Kusaka et al., 1994; Wang et al., 2000; Yeh et al., 2000; Zhang et al., 2000; Kim et al., 2004). Previously, inhibition of MetAP2 by TNP470 has been shown to activate p53 for cell-cycle arrest (Yeh et al., 2000; Zhang et al., 2000).
The Src family kinases have been shown to play pivotal roles in cell-cycle progression, making them potential candidates to mediate the cell-cycle effects of MetAP inhibitors. MetAP2 plays a critical role in the proliferation of endothelial cells and certain tumor cells and thus serves as a promising target for anti-angiogenesis and anti-cancer drugs (Bo et al., 2004). The inhibition of MetAP2 expression in mesothelioma cells leads to cell death and that such apoptosis is avoided in cases where there is overexpression of Bcl-2 (Catalano et al., 2001). The upregulation of Bcl-2 in colorectal cancer is well established by various investigators (Rajala et al., 2000; Yu et al., 2003; Valassiadou et al., 1997).
  

Bibliography

A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells.
Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y.
Cancer Res. 1994 Jul 1;54(13):3407-12.
PMID 8012959
 
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M.
Bioorg Med Chem. 2004 Jul 15;12(14):3871-83.
PMID 15210154
 
AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.
Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V.
Cancer Res. 1994 Apr 15;54(8):2073-6.
PMID 7513609
 
Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis.
Bo H, Ghazizadeh M, Shimizu H, Kurihara Y, Egawa S, Moriyama Y, Tajiri T, Kawanami O.
J Nippon Med Sch. 2004 Jun;71(3):172-80.
PMID 15226608
 
N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families.
Bradshaw RA, Brickey WW, Walker KW.
Trends Biochem Sci. 1998 Jul;23(7):263-7. (REVIEW)
PMID 9697417
 
Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity.
Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A.
Am J Pathol. 2001 Aug;159(2):721-31.
PMID 11485930
 
Induction of apoptosis due to lowering the level of eukaryotic initiation factor 2-associated protein, p67, from mammalian cells by antisense approach.
Datta B, Datta R.
Exp Cell Res. 1999 Feb 1;246(2):376-83.
PMID 9925753
 
Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS.
J Clin Oncol. 1998 Apr;16(4):1444-9.
PMID 9552050
 
Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.
Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO.
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15183-8.
PMID 9860943
 
Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression.
Hu X, Addlagatta A, Lu J, Matthews BW, Liu JO.
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18148-53. Epub 2006 Nov 17.
PMID 17114291
 
Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases.
Hu X, Dang Y, Tenney K, Crews P, Tsai CW, Sixt KM, Cole PA, Liu JO.
Chem Biol. 2007 Jul;14(7):764-74.
PMID 17656313
 
Role of methionine in the initiation of haemoglobin synthesis.
Jackson R, Hunter T.
Nature. 1970 Aug 15;227(5259):672-6.
PMID 5432061
 
High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts.
Kanno T, Endo H, Takeuchi K, Morishita Y, Fukayama M, Mori S.
Lab Invest. 2002 Jul;82(7):893-901.
PMID 12118091
 
Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides.
Kim S, LaMontagne K, Sabio M, Sharma S, Versace RW, Yusuff N, Phillips PE.
Cancer Res. 2004 May 1;64(9):2984-7.
PMID 15126329
 
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Kruger EA, Figg WD.
Expert Opin Investig Drugs. 2000 Jun;9(6):1383-96. (REVIEW)
PMID 11060750
 
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ.
Clin Cancer Res. 1997 Sep;3(9):1501-5.
PMID 9815836
 
Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).
Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J.
Br J Cancer. 1994 Feb;69(2):212-6.
PMID 8297716
 
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.
Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM, Shusterman S.
Clin Cancer Res. 2005 Apr 1;11(7):2680-5.
PMID 15814649
 
Increased expression of N-myristoyltransferase in gallbladder carcinomas.
Rajala RV, Radhi JM, Kakkar R, Datla RS, Sharma RK.
Cancer. 2000 May 1;88(9):1992-9.
PMID 10813869
 
Potential role of N-myristoyltransferase in cancer.
Selvakumar P, Lakshmikuttyamma A, Shrivastav A, Das SB, Dimmock JR, Sharma RK.
Prog Lipid Res. 2007 Jan;46(1):1-36. Epub 2006 Jun 12. (REVIEW)
PMID 16846646
 
Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis.
Sheen IS, Jeng KS, Jeng WJ, Jeng CJ, Wang YC, Gu SL, Tseng SY, Chu CM, Lin CH, Chang KM.
World J Gastroenterol. 2005 Feb 14;11(6):771-7.
PMID 15682466
 
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM.
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6099-103.
PMID 9177176
 
Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal.
Solbiati J, Chapman-Smith A, Miller JL, Miller CG, Cronan JE Jr.
J Mol Biol. 1999 Jul 16;290(3):607-14.
PMID 10395817
 
Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors.
Towbin H, Bair KW, DeCaprio JA, Eck MJ, Kim S, Kinder FR, Morollo A, Mueller DR, Schindler P, Song HK, van Oostrum J, Versace RW, Voshol H, Wood J, Zabludoff S, Phillips PE.
J Biol Chem. 2003 Dec 26;278(52):52964-71. Epub 2003 Oct 8.
PMID 14534293
 
Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation.
Tucker LA, Zhang Q, Sheppard GS, Lou P, Jiang F, McKeegan E, Lesniewski R, Davidsen SK, Bell RL, Wang J.
Oncogene. 2008 Jun 26;27(28):3967-76. Epub 2008 Feb 11.
PMID 18264137
 
Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Georgoulias V, Melissas J, Tsiftsis DD, Delides G, Kanavaros P.
Anticancer Res. 1997 Jul-Aug;17(4A):2571-6.
PMID 9252682
 
Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases.
Wang J, Lou P, Henkin J.
J Cell Biochem. 2000 Apr;77(3):465-73.
PMID 10760954
 
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.
Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R, Henkin J.
Cancer Res. 2003 Nov 15;63(22):7861-9.
PMID 14633714
 
The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.
Yeh JR, Mohan R, Crews CM.
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12782-7.
PMID 11070090
 
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1.
Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO.
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6427-32.
PMID 10841547
 

Citation

This paper should be referenced as such :
Selvakumar, P ; Sharma, RK
METAP2 (methionyl aminopeptidase 2)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(6):562-565.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/METAP2ID46053ch12q22.html


External links

Nomenclature
HGNC (Hugo)METAP2   16672
Cards
AtlasMETAP2ID46053ch12q22
Entrez_Gene (NCBI)METAP2  10988  methionyl aminopeptidase 2
AliasesMAP2; MNPEP; p67eIF2
GeneCards (Weizmann)METAP2
Ensembl hg19 (Hinxton)ENSG00000111142 [Gene_View]  chr12:95867822-95909613 [Contig_View]  METAP2 [Vega]
Ensembl hg38 (Hinxton)ENSG00000111142 [Gene_View]  chr12:95867822-95909613 [Contig_View]  METAP2 [Vega]
ICGC DataPortalENSG00000111142
TCGA cBioPortalMETAP2
AceView (NCBI)METAP2
Genatlas (Paris)METAP2
WikiGenes10988
SOURCE (Princeton)METAP2
Genetics Home Reference (NIH)METAP2
Genomic and cartography
GoldenPath hg19 (UCSC)METAP2  -     chr12:95867822-95909613 +  12q22   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)METAP2  -     12q22   [Description]    (hg38-Dec_2013)
EnsemblMETAP2 - 12q22 [CytoView hg19]  METAP2 - 12q22 [CytoView hg38]
Mapping of homologs : NCBIMETAP2 [Mapview hg19]  METAP2 [Mapview hg38]
OMIM601870   
Gene and transcription
Genbank (Entrez)AK055692 AK091730 AK125296 AK300836 AK315559
RefSeq transcript (Entrez)NM_001317182 NM_001317183 NM_006838
RefSeq genomic (Entrez)NC_000012 NC_018923 NT_029419 NW_004929384
Consensus coding sequences : CCDS (NCBI)METAP2
Cluster EST : UnigeneHs.444986 [ NCBI ]
CGAP (NCI)Hs.444986
Alternative Splicing GalleryENSG00000111142
Gene ExpressionMETAP2 [ NCBI-GEO ]   METAP2 [ EBI - ARRAY_EXPRESS ]   METAP2 [ SEEK ]   METAP2 [ MEM ]
Gene Expression Viewer (FireBrowse)METAP2 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10988
GTEX Portal (Tissue expression)METAP2
Protein : pattern, domain, 3D structure
UniProt/SwissProtP50579   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP50579  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP50579
Splice isoforms : SwissVarP50579
PhosPhoSitePlusP50579
Domaine pattern : Prosite (Expaxy)MAP_2 (PS01202)   
Domains : Interpro (EBI)Pept_M24_MAP    Pept_M24_structural-domain    Pept_M24A_MAP2    Pept_M24A_MAP2_BS    WHTH_DNA-bd_dom   
Domain families : Pfam (Sanger)Peptidase_M24 (PF00557)   
Domain families : Pfam (NCBI)pfam00557   
Conserved Domain (NCBI)METAP2
DMDM Disease mutations10988
Blocks (Seattle)METAP2
PDB (SRS)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
PDB (PDBSum)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
PDB (IMB)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
PDB (RSDB)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
Structural Biology KnowledgeBase1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
SCOP (Structural Classification of Proteins)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
CATH (Classification of proteins structures)1B59    1B6A    1BN5    1BOA    1KQ0    1KQ9    1QZY    1R58    1R5G    1R5H    1YW7    1YW8    1YW9    2ADU    2EA2    2EA4    2GA2    2OAZ    5CLS    5D6E    5D6F   
SuperfamilyP50579
Human Protein AtlasENSG00000111142
Peptide AtlasP50579
HPRD03522
IPIIPI00033036   IPI01010256   IPI00789396   IPI01021994   IPI01022810   IPI01022693   IPI01022532   IPI01022237   IPI01020989   
Protein Interaction databases
DIP (DOE-UCLA)P50579
IntAct (EBI)P50579
FunCoupENSG00000111142
BioGRIDMETAP2
STRING (EMBL)METAP2
ZODIACMETAP2
Ontologies - Pathways
QuickGOP50579
Ontology : AmiGOaminopeptidase activity  aminopeptidase activity  cytoplasm  cytosol  plasma membrane  metalloexopeptidase activity  protein processing  peptidyl-methionine modification  regulation of rhodopsin mediated signaling pathway  N-terminal protein amino acid modification  poly(A) RNA binding  metal ion binding  metalloaminopeptidase activity  protein initiator methionine removal  
Ontology : EGO-EBIaminopeptidase activity  aminopeptidase activity  cytoplasm  cytosol  plasma membrane  metalloexopeptidase activity  protein processing  peptidyl-methionine modification  regulation of rhodopsin mediated signaling pathway  N-terminal protein amino acid modification  poly(A) RNA binding  metal ion binding  metalloaminopeptidase activity  protein initiator methionine removal  
NDEx NetworkMETAP2
Atlas of Cancer Signalling NetworkMETAP2
Wikipedia pathwaysMETAP2
Orthology - Evolution
OrthoDB10988
GeneTree (enSembl)ENSG00000111142
Phylogenetic Trees/Animal Genes : TreeFamMETAP2
HOVERGENP50579
HOGENOMP50579
Homologs : HomoloGeneMETAP2
Homology/Alignments : Family Browser (UCSC)METAP2
Gene fusions - Rearrangements
Fusion : MitelmanGNB3/METAP2 [12p13.31/12q22]  [t(12;12)(p13;q22)]  
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMETAP2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)METAP2
dbVarMETAP2
ClinVarMETAP2
1000_GenomesMETAP2 
Exome Variant ServerMETAP2
ExAC (Exome Aggregation Consortium)METAP2 (select the gene name)
Genetic variants : HAPMAP10988
Genomic Variants (DGV)METAP2 [DGVbeta]
DECIPHER (Syndromes)12:95867822-95909613  ENSG00000111142
CONAN: Copy Number AnalysisMETAP2 
Mutations
ICGC Data PortalMETAP2 
TCGA Data PortalMETAP2 
Broad Tumor PortalMETAP2
OASIS PortalMETAP2 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMETAP2  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDMETAP2
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch METAP2
DgiDB (Drug Gene Interaction Database)METAP2
DoCM (Curated mutations)METAP2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)METAP2 (select a term)
intoGenMETAP2
NCG5 (London)METAP2
Cancer3DMETAP2(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM601870   
Orphanet
MedgenMETAP2
Genetic Testing Registry METAP2
NextProtP50579 [Medical]
TSGene10988
GENETestsMETAP2
Huge Navigator METAP2 [HugePedia]
snp3D : Map Gene to Disease10988
BioCentury BCIQMETAP2
ClinGenMETAP2
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10988
Chemical/Pharm GKB GenePA30765
Clinical trialMETAP2
Miscellaneous
canSAR (ICR)METAP2 (select the gene name)
Probes
Litterature
PubMed56 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMETAP2
EVEXMETAP2
GoPubMedMETAP2
iHOPMETAP2
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:44:18 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.